References
- Duckitt D, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330:565–7
- Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modeling. Health Technol Assess 2008;12:1–270
- Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004;18:383–96
- Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology 2009;24:147–58
- Madazli R, Kuseyrioglu B, Uzun H, et al. Prediction of preeclampsia with maternal mid-trimester placental growth factor, activin A, fibronectin and uterine artery Doppler velocimetry. Int J Gynecol Obstet 2005;89:251–7
- Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase-1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–58
- Woods AK, Hoffmann DS, Weydert CJ, et al. Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension 2011;57:94–102
- Levine RJ, Maynard SE, Qian C, et al. Circulation angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83
- Chaiworapongsa T, Romero R, Espinoza J, et al. Evidence supporting a role blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am J Obstet Gynecol 2004;190:1547–50
- Unal ER, Robinson CJ, Johnson DD, Chang EY. Second-trimester angiogenic factors as biomarkers for future onset preeclampsia. Am J Obstet Gynecol 2007;197:211.e1–4
- Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007;196:326.e1–13
- Muller PR, James AH, Murtha PP, et al. Circulating angiogenic factor and abnormal uterine artery Doppler velocimetry in the second trimester. Hypertens Pregnancy 2006;25:183–92
- Hadker, N. Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. J Med Econ 2010;13:728–37
- National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:1–22
- Sibai BM, Dekker GA, Kuplerminc M. Pre-eclampsia. Lancet 2005;365:785–99
- Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. Mol Aspects Med 2007;28:227–44
- Vatten LJ, Eskild A, Nilsen TIL, et al. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 2007;196:239.e1–6
- Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007;197:244.e1–8
- Sibai BM, Koch MA, Freire S, et al. Serum inhibin A and angiogenic factors levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for subsequent preeclampsia? Am J Obstet Gynecol 2008;199:268.e1–9
- Parra M, Rodrigo R, Barja P, et al. Screening test for preeclampsia through assessment of utero placental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am J Obstet Gynecol 2005;193:1486–91
- Teixeira PG, Cabral AC, Andrade SP, et al. Placental growth factor (PLGF) is a surrogate marker in preeclamptic hypertension. Hypertens Pregnancy 2008;27:65–73